AQST
NASDAQAquestive Therapeutics Inc.
News · 26 weeks66+40%
2026-03-012026-08-23
Mix2390d
- Insider12(52%)
- SEC Filings7(30%)
- Other2(9%)
- Earnings2(9%)
Latest news
25 items- INSIDERPresident and CEO Barber Daniel sold $107,168 worth of shares (25,000 units at $4.29), decreasing direct ownership by 4% to 585,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Commercial Officer Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 1% to 235,689 units (SEC Form 4) (tax withholding)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECSEC Form 10-Q filed by Aquestive Therapeutics Inc.10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateSuccessfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues pre-launch medical affairs activities and payer engagementOn track to begin ex-U.S. filings of Anaphylm in Q4 2026Company to host investor call on August 12, 2026, at 8:00 a.m. ET WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the s
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual FilmHuman factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK resultsRevised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 secondsRevised instructions for use reduced incorrect film placement from previous human factors validation study by over 80% Top-of-tongue PK arm showed clinically meaningful pharmacodynamic (PD) results WARREN, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing me
- PRAquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ETWARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2026, and provide an update on recent developments in its business after market close on Tuesday, August 11, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Wednesday, August 12, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc
- INSIDERPresident and CEO Barber Daniel sold $100,192 worth of shares (25,000 units at $4.01), decreasing direct ownership by 4% to 610,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECSEC Form 424B3 filed by Aquestive Therapeutics Inc.424B3 - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECSEC Form EFFECT filed by Aquestive Therapeutics Inc.EFFECT - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and MetabolismWARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host 1x1 investor meetings on July 14, 2026. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I), and metabolism. About Aquestive Therapeutics, Inc.Aquestive is a pharmaceutical company advancing medicines to bring meaningf
- SECSEC Form S-3 filed by Aquestive Therapeutics Inc.S-3 - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- INSIDERDirector Krop Julie exercised 25,000 shares at a strike of $0.71 and sold $125,392 worth of shares (25,000 units at $5.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel sold $104,010 worth of shares (25,000 units at $4.16), decreasing direct ownership by 4% to 635,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Morris Timothy E4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Krop Julie4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Jenkins Abigail L.4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Cochran John4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Brown Gregory B4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Director Taglietti Marco4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- INSIDERChief Commercial Officer Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 1% to 238,403 units (SEC Form 4) (for withholding tax)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Legal Officer Zalewski Thomas A. was granted 100,000 shares (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel sold $35,413 worth of shares (8,257 units at $4.29), decreasing direct ownership by 1% to 660,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
AQST FAQ
7 questionsWhat does Aquestive Therapeutics Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The...Where does AQST stock trade?
Aquestive Therapeutics Inc. (AQST) is listed on NASDAQ.What sector and industry is AQST in?
Aquestive Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aquestive Therapeutics Inc. go public?
Aquestive Therapeutics Inc. (AQST) completed its IPO in 2018.What are analysts saying about AQST?
Aquestive Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $800.00 price target on 2026-04-24. Recent price targets range from $700.00 to $1700.00.What companies are similar to AQST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AQST side-by-side with any of them on Quantisnow.How can I track AQST on Quantisnow?
Quantisnow aggregates Aquestive Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AQST to receive live email and push alerts on every new disclosure.